Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr:30 Suppl 1:26-32.
doi: 10.1111/jvh.13811. Epub 2023 Feb 27.

Bulevirtide-based treatment strategies for chronic hepatitis delta: A review

Elisabetta Degasperi  1 , Maria Paola Anolli  1 , Pietro Lampertico  1   2
Affiliations
Free article
Review

Bulevirtide-based treatment strategies for chronic hepatitis delta: A review

Elisabetta Degasperi et al. J Viral Hepat. 2023 Apr.
Free article

Abstract

Chronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. Until recently, the only therapeutic approach has been the off-label use of a 48 weeks course of PegInterferon alpha (PegIFNα), that was characterized by suboptimal efficacy and burdened by significant side effects that limited treatment applicability in patients with advanced liver disease. In July 2020, European Medicines Agency (EMA) conditionally approved the entry inhibitor Bulevirtde (BLV) at the dose of 2 mg/day for the treatment of adult patients with compensated CHD. Efficacy and safety of BLV in CHD have been evaluated in clinical trials either as monotherapy or in combination with PegIFNα. These results were confirmed by real-life studies, which also evaluated long-term BLV monotherapy in patients with advanced compensated cirrhosis. Notwithstanding these promising results there are still several issues to be addressed, such as the optimal duration of the treatment, the rates of off-therapy responses, as well as the long-term clinical benefits. This review summarizes updated and current literature data about clinical trials and real-life studies with BLV monotherapy and/or in combination with PegIFNα.

Keywords: HDV; HDV-RNA; bulevirtide; chronic delta hepatitis; cirrhosis; combined response; entry inhibitor; virological response.

PubMed Disclaimer

References

REFERENCES

    1. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523-532.
    1. Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of Hepatitis Delta virus infection. J Infect Dis. 2020;221:1677-1687.
    1. Rizzetto M, Hamid S, Negro F. The changing context of hepatits D. J Hepatol. 2021;74:1200-1211.
    1. Wedemeyer H, Yurdaydin C, Hardtke S, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019;19:275-286.
    1. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70:1782-1794.